Theravance Biopharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Theravance Biopharma generated cash of -$26,997,000, which is more than the previous year. Cash used in financing activities reached the amount of -$198,933,000 last year. Net change in cash is therefore -$258,627,000.
Cash Flow
| 2014 | -175.15M | -106.25M | 370.62M |
|---|---|---|---|
| 2015 | -168.85M | 111.03M | 81.31M |
| 2016 | -98.98M | -148.23M | 479.22M |
| 2017 | -201.05M | -56.33M | 1.65M |
| 2018 | -112.86M | 176.70M | 225.2M |
| 2019 | -238.19M | -83.05M | 1.29M |
| 2020 | -250.40M | 10.72M | 263.08M |
| 2021 | -207.85M | 124.49M | 91.86M |
| 2022 | -186.99M | 1.15B | -758.80M |
| 2023 | -26.99M | -32.69M | -198.93M |
TBPH Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 299.00M | 90.79M | 82.3M | 58.89M | 378.85M | 89.81M | 344.70M | 112.70M | 89.21M | -281.40M |
Operating activities | ||||||||||
Net income | -55.19M | -92.82M | -199.42M | -278.01M | -236.45M | -215.52M | -285.40M | -190.66M | -182.21M | -237.03M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 4.25M | 7.02M | 9.70M | 9.06M | 6.21M | 3.16M | 4.02M | 3.11M | 2.98M | 2.66M |
Stock-based compensation expense | 25.37M | 39.73M | 62.06M | 62.97M | 60.45M | 0 | 49.14M | 41.16M | 54.05M | 43.23M |
| Deferred income tax benefit | 25.37M | 39.73M | 62.06M | 62.97M | 60.45M | 0 | 49.14M | 41.16M | 54.05M | 43.23M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | -2.72M | 1.80M | 6.12M | -11.32M | 1.63M | -1.60M | 1.27M | -1.63M | -90K |
Inventories | 0 | 0 | -26.39M | -22.52M | 1.44M | -1.62M | -7.30M | -3.18M | 1.03M | -6.62M |
Accounts payable | 6K | -1.61M | -3.53M | 3.65M | -4.27M | 3.57M | 3.79M | -16.43M | 8.71M | 3.91M |
Cash generated by operating activities | -26.99M | -186.99M | -207.85M | -250.40M | -238.19M | -112.86M | -201.05M | -98.98M | -168.85M | -175.15M |
Investing activities | ||||||||||
Purchases Of Investments | -134.53M | -103.14M | -158.30M | -401.98M | -423.89M | -183.26M | -288.79M | -237.56M | -73.01M | -168.89M |
Investments In Property Plant And Equipment | -2.48M | -572K | -3.40M | -6.61M | -3.17M | -7.24M | -2.40M | -2.13M | -2.64M | -3.10M |
Acquisitions Net | 0 | 4.57M | 6K | 64K | 5M | 20M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -32.69M | 1.15B | 124.49M | 10.72M | -83.05M | 176.70M | -56.33M | -148.23M | 111.03M | -106.25M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 111.65M | 139.91M | 3.47M | 1.39M | 0 | 253.02M | 79.01M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -199.55M | -132.28M | -9.06M | -9.74M | -3.17M | -9.80M | -8.56M | -3.87M | -756K | -178K |
Repayments of term debt | 0 | -631.60M | -10.73M | -246.81M | -2.15M | -229.44M | 0 | -222.49M | 0 | 0 |
Cash used in financing activities | -198.93M | -758.80M | 91.86M | 263.08M | 1.29M | 225.2M | 1.65M | 479.22M | 81.31M | 370.62M |
Net Change In Cash | -258.62M | 208.21M | 8.49M | 23.40M | -319.95M | 289.04M | -255.72M | 232.00M | 23.49M | 370.62M |
Cash at end of period | 40.38M | 299.00M | 90.79M | 82.3M | 58.89M | 378.85M | 88.98M | 344.70M | 112.70M | 89.21M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |